Consortium History - Five-Year Milestone: Moving to the Future
(August 30, 2009)

Asia Consortium Introduction
Fast Growth of Asia Consortium Membership
Merge of ISPOR Asia/Asia-Pacific Organizations
Asia Consortium Restructure Initiatives
Asia Consortium Restructure History
Asia Consortium Restructure Working Team
Asia Consortium New Structure
Asia Consortium Restructure Working Team Directory
Asia Consortium Executive Committee Directory
Asia Consortium Advisory Committee Directory
Asia-Pacific Medical Device & Diagnostics Council Directory
Medical Device and Diagnostics News

*****************************************************************************************

Asia Consortium Introduction

ISPOR Asia Consortium was initiated in September 2003 in Kobe, Japan during the ISPOR 1st Asia-Pacific Conference and officially formed in July 2004. The organizational structure is composed of the Executive Committee and Advisory Committee. The Executive Committee consists of members from Asian countries, with up to three representatives from any one country (exclusive of the ISPOR Regional Chapter representation and ISPOR Asia-Pacific Conference chairs). The Advisory Committee consists of members from Asia as well as other regions, with the criteria of a new membership approved by the Executive Committee. The Executive Committee is defined to initiate and facilitate ISPOR activities in the region and makes suggestions to the ISPOR Board of Directors on scientific and health policy issues important in the region, and the Advisory Committee advises the Executive Committee on new initiatives, health science or health policy issues, and other activities of the Consortium.

 

Under the leadership of the Executive Committee and the Advisory Committee, in the past five years, the Asia Consortium has co-organized the 2nd and 3rd ISPOR Asia-Pacific Conference, in which 750 and 859 attendees participated respectively; developed the 1st and 2nd Value in Health Asia Special Issue published or to be published in 2008 and 2009; conducted a Needs Survey of Pharmacoeconomics (health economics) and Outcomes Research completed in May 2009 and the report is to be submitted to the ISPOR Board of Directors in October; and initiated a number of country/region-based events through the ISPOR Regional Chapters in the region.

 

Fast Growth of Asia Consortium Membership


Motivated by the achieved successes, in the past years the Asia Consortium membership has grown significantly:

  • The number of members on the Executive Committee has increased from the initial 9 founding members to 31, and 3 founding members to 35 on the Advisory Committee. The member directory is given below.
  • The number of countries/areas represented on the Executive Committee have increased from  7 (China Mainland, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand) to 13 (adding India, Malaysia, Pakistan, Philippines, Indonesia and Mongolia), and the number of countries/areas on the Advisory Committee from 1 (USA) to 9 (adding Japan, South Korea, Singapore, Pakistan, Taiwan, Australia, France, and Switzerland);
  • The number of ISPOR Regional Chapters in Asia (exclusive of the central Asia and Middle East) have increased from 2 (Hong Kong Chapter and Taiwan Chapter) to 9 (adding Japan Chapter, Chinese MDA-PE Chapter, Thailand Chapter, India Chapter, Shanghai Chapter, Malaysia Chapter, and Pakistan Chapter), with over 500 chapter members; 
  • More than 30 professionals who are interested in joining the Asia Consortium are on a waiting list now, however many of them may not be able to obtain a membership due to either the limitation of country representation to the Executive Committee, or the quality requirement of a membership to the Advisory Committee; and
  • Over 1200 people in Asian region are currently an ISPOR member or in the ISPOR network, who are potential members of the Asia Consortium.

Merge of ISPOR Asia/Asia-Pacific Organizations

To provide a unified approach to health care issues in Asia and to provide a platform that may include different stakeholders from all health care sectors in Asia and Asia-Pacific region, the ISPOR Asia-Pacific Medical Device & Diagnostics Council (ISPOR APMDD Council) and the ISPOR Health Technology Assessment Council Asia (ISPOR HTA Council Asia) were merged into the ISPOR Asia Consortium. The ISPOR APMDD Council was founded in March 2006 following the ISPOR 2nd Asia-Pacific Conference in Shanghai, China. Currently, the Council has 24 Council members, and 7 Advisory Committee members from work environments of government, academia, hospital, non-academic research organizations, and industry (http://www.ispor.org/councils/MDDcouncil.asp). The ISPOR HTA Council Asia conducted its first meeting in September 2008 following the ISPOR 3rd Asia-Pacific Conference in Seoul, South Korea. Seventeen attendees participated in the meeting (http://www.ispor.org/councils/HTA_council.asp). The ISPOR Asia-Pacific Medical Device & Diagnostics Council and its Advisory Committee Directory is given below.

Asia Consortium Restructure Initiatives


To meet the challenges of the rapid growth of the organization and the increasing interest in the science of pharmacoeconomics (health economics) and outcomes research in Asia, restructuring the Asia Consortium was suggested. Dr. Shanlian Hu, founding member and 2008-2010 Chair of the Executive Committee, suggested creating an ISPOR Asian special fund to sponsor health care decision-makers in Asian countries to participate in the Consortium’s activities including the ISPOR Asia-Pacific Conferences. Dr. Hong Li, founding member and 2005-2007 Chair of the Advisory Committee, suggested establishing special groups to address issues that are common and important to the region. The Needs Survey suggested a more open structure organization. Over the past year, the restructure of the Asia Consortium was discussed among members via phones, emails or meetings. In May 2009, the first draft of the revised ISPOR Asia Consortium Policies and Procedures (including the revised organizational structure) was prepared for Consortium members to review.

 

Asia Consortium Restructure History


The first draft of new ISPOR Asia Consortium Policies and Procedures was discussed at the Asia Consortium Executive Committee and Advisory Committee Joint Business Meeting on May 18, 2009 in Orlando, USA, in which under the supervision of the Executive Committee four committees were suggested: Education Committee, Pharmaceuticals Committee, Medical Devices & Diagnostics Committee, and Health Technology Assessment Committee. Based on members’ feedbacks collected at the business meeting and via emails, the second and third drafts were developed and discussed at the joint teleconference of the Executive Committee and Advisory Committee on June 9, 2009, in which eight committees were proposed, including three task-oriented committees: Asia-Pacific Conference Program Committee, Education Committee, and Publication Committee, and five work environment-oriented committees: Decision-Maker Committee, Clinical Practitioner Committee, Student Chapter Committee, Health Technology Producer (Industry) Committee, and Health Education & Research Organization Committee. The second and third drafts were stated as a “right direction” and were suggested to be a basis for a further discussion. Since in Asia there are only two ISPOR Student Chapters: National University of Singapore Chapter and China Pharmaceutical University Chapter, the Student Chapter Committee was deleted in the fourth draft, which was discussed at the Asia Consortium Founding Member teleconference on June 16, 2009, when a special working team suggested led by the current chair of the Executive Committee was recommended to further work on the Consortium’s new structure and the new policies and procedures.

 

Asia Consortium Restructure Working Team


The Asia Consortium Restructure Working Team was led by Dr. Shanlian Hu, 2008-2010 Chair of the ISPOR Asia Consortium Executive Committee. Dr. Hu invited Dr. Mingliang Zhang, 2009-2011 Chair of the Advisory Committee to co-chair the Working Team. Dr. Hu and Dr. Zhang invited the following to be on the board:

  • ISPOR Asia Consortium representatives:
  • Chair-Elect of the Asia Consortium Executive Committee and Advisory Committee,
  • Past chairs of the Asia Consortium Executive Committee and Advisory Committee, and
  • Representatives of consulting organizations on the Asia Consortium.
  • ISPOR Asia-Pacific Medical Device & Diagnostics Council Representatives:
  • Current Chair and Vice Chair of the Council,
  • Current Chair of the Council Advisory Committee, and
  • Representatives of the Council members.
  • ISPOR Health Technology Assessment Council Asia:
  • Representatives of the Council members.
  • Past Directors on the ISPOR Board of Directors from Asia were also invited as advisors of the Working Team.

The Asia Consortium Restructure Working Team Directory is given below.

 

Asia Consortium New Structure*


Worked on the fourth draft, the Asia Consortium Restructure Working Team completed its edition on October 15, 2009, and proposed the new Asia Consortium Policies and Procedures to all members of the Asia Consortium Executive Committee and Advisory Committee for endorsement. The new organizational structure included in the proposal is below:

 

The ISPOR Asia Consortium is composed of the Executive Committee, the Advisory Committee, seven Working Committees, and ten Working Subcommittees as follows. The Executive Committee is the governing body. The Advisory Committee is an advisory body to the Executive Committee.

 

The Working Committees, including Subcommittees, are as follows:

  • ISPOR Asia-Pacific Conference Program Committee, including four subcommittees:
  • ISPOR Asia-Pacific Conference Program Research Review Committee
  • ISPOR Asia-Pacific Conference Program Health Care Decision-Maker Case Study Review Committee
  • ISPOR Asia-Pacific Conference Program Workshop Review Committee
  • ISPOR Asia-Pacific Conference Program Issue Panel Review Committee
  • ISPOR Asia Consortium Education Committee, including two subcommittees:
  • ISPOR Conference Short Course Committee
  • ISPOR Distance Learning & Onsite Training Committee
  • ISPOR Asia Consortium Publication Committee, including two subcommittees:
  • Value in Health Special Issue Committee
  • ISPOR Good Outcomes Research Practices & Publications Committee
  • ISPOR Asia Consortium Health Technology Producers (Industry) Committee, including two subcommittees
  • Pharmaceuticals & Biologics Committee
  • Medical Devices & Diagnostics Committee
  • ISPOR Asia Consortium Health Care Providers Committee;
  • ISPOR Asia Consortium Health Technology Assessment Agencies Committee; and
  • ISPOR Asia Consortium Health Care Policymakers & Payers Committee.

Based on the new Asia Consortium Policies and Procedures, a generic version of ISPOR Regional Consortia Policies and Procedures was developed and presented (by Dr. Shanlian Hu) at the ISPOR Board of Directors’ meeting on October 24, 2009 during the ISPOR 12th European Congress in Paris. The Board approved the ISPOR Regional Consortia Policies and Procedures.

 

*Summarized after the ISPOR Board of Directors’ meeting.

Asia Consortium Restructure Working Team Directory

Co-Chairs:

1. Shanlian Hu MD, MSc, 2008-2010 Chair, Asia Consortium Executive Committee, Co-chair, ISPOR 2nd Asia-Pacific Conference & Professor, Training Center for Health Management, School of Public Health, Fudan University, and Director, Center for Health Development Research, Shanghai Bureau of Health, Shanghai Municipal Government, Shanghai, China

 

2, Mingliang Zhang PhD, 2009-2011 Chair, Asia Consortium Advisory Committee & Senior Director, Health Economics Immunology, Worldwide Health Economics and Pricing, Johnson and Johnson Pharmaceutical Services, Raritan, NJ, USA

Members Representing ISPOR Asia Consortium Executive Committee and Advisory Committee:

3, Bong-Min Yang PhD, 2010-2012 Chair-Elect, Asia Consortium Executive Committee, Chair, ISPOR 3rd Asia-Pacific Conference & Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea

 

4, Jennifer Sung PharmD, MS, 2009-2011 Chair-Elect, Asia Consortium Advisory Committee & Executive Director, Global Health Economics & Outcomes Research (HE & OR), Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

 

5, Kenneth KC Lee JP, BSc(Pharm), MPhil, PhD, 2006-2008 Chair, Asia Consortium Executive Committee & Professor and Associate Director (External Affairs), School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, China

 

6, Jeff J. Guo B. Pharm., PhD, 2007-2009 Chair, Asia Consortium Advisory Committee Associate Professor of Pharmacoeconomics & Pharmacoepidemiology, James L. Winkle College of Pharmacy (& Faculty Research Fellow, Institute for the Study of Health), University of Cincinnati Medical Center, Cincinnati, OH,  USA

 

7, Gordon G. Liu PhD, 2004-2006 Chair, Asia Consortium Executive Committee & Professor of Economics, and Executive Director, The Health Economics and Management Institute, Guanghua School of Management, Peking University, Beijing, China

 

8, Hong Li PhD, MPH, 2005-2007 Chair, Asia Consortium Advisory Committee & Group Director, Outcomes Research, and Vice President, Market Access, China, Bristol-Myers Squibb Company Asia-Pacific, Singapore

9, Bruce Crawford MA, MPH, Representative of members from research/consulting companies & General Manager, Asia, Adelphi Values, Tokyo, Japan

 

Members Representing ISPOR Asia-Pacific Medical Device & Diagnostics Council

10, Jie Chen PhD, 2008-2010 Chair, ISPOR Asia-Pacific Medical Device & Diagnostics Council & Director, Key Lab of Health Technology Assessment of Ministry of Health, and Professor, School of Public Health, Fudan University, Shanghai, China

 

11, Miguel Valentin, 2008-2010 Chair, ISPOR Asia-Pacific Medical Device & Diagnostics Council Advisory Committee & Director, Health Economics – International, Boston Scientific Corporation, Natick, MA, USA

 

12, Ashoke Bhattacharjya PhD, Funding Member of  the ISPOR Asia-Pacific Medical Device & Diagnostics Council & Executive Director, Health Outcomes and Policy, Johnson & Johnson Medical Asia Pacific, India

 

13, Sang Soo Lee MBA, Funding Member of the ISPOR Asia-Pacific Medical Device & Diagnostics Council & Therapy Value Partner Manager, Reimbursement, PR and Web-Communication, Medtronic Korea Co., Ltd., Seoul, South Korea

 

Members Representing ISPOR Health Technology Assessment (HTA) Council Asia

14. Tony Yen-Huei Tarn MS, PhD, Representative of ISPOR Health Technology Assessment Council Asia & Senior Researcher, Health Technology Assessment Task Force, Center for Drug Evaluation, Taipei, Taiwan

 

Hon Advisors: Past Directors of ISPOR Borad of Directors Repsenting ISPOR Asian Membership

15. Isao Kamae MD, DrPH, 2004-2006 ISPOR Board of Directors, Co-chair, ISPOR 1st Asia-Pacific Conference & Professor and Chair, Graduate School of Health Management, Keio University, Tokyo, Japan

 

16. Shu-Chuen Li PhD, MS, MBA, 2006-2008 ISPOR Board of Directors & Professor, Chair and Head, Discipline of Pharmacy & Experimental Pharmacology, School of Biomedical Sciences, University of Newcastle, Callaghan, NSW, Australia, and Visiting Professor, Department of Pharmacy National University of Singapore, Republic of Singapore

Asia Consortium Executive Committee Directory

2008-2010 Chair

 

Shanlian Hu MD, MSc, Chair, ISPOR 2nd Asia-Pacific Conference, President, ISPOR Chinese MDA-PE Chapter, Professor, Training Center for Health Management, School of Public Health, Fudan University, and Director, Center for Health Development Research, Shanghai Bureau of Health, Shanghai, China

 

2008-2010 Chair-elect and 2010-2012 Chair

Bong-Min Yang PhD, ISPOR 3rd Asia-Pacific Conference Chair, and Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea

 

Members

 

China Mainland

 

Wen Chen PhD, Co-chair, ISPOR 2nd Asia-Pacific Conference, Interim President, ISPOR Shanghai Chapter, Professor and Associate Dean, School of Public Health, Fudan University, Shanghai, China

 

Shanlian Hu MD, MSc, Co-chair, ISPOR 2nd Asia-Pacific Conference, President, ISPOR Chinese MDA-PE Chapter, Professor, Training Center for Health Management, School of Public Health, Fudan University, and Director, Center for Health Development Research, Shanghai Bureau of Health, Shanghai, China

 

Gordon G. Liu PhD, 2004-2006 Chair, ISPOR Asia Consortium Executive Committee, and Professor of Economics, Executive Director, The Health Economics and Management Institute, Peking University Guanghua School of Management, Beijing, China

 

Hong Kong

 

Kenneth KC Lee JP, BSc(Pharm), MPhil, PhD, 2006-2008 Chair, ISPOR Asia Consortium Executive Committee, and Professor and Associate Director (External Affairs), School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, China

 

Taiwan

 

Tony Yen-Huei Tarn MS, PhD, Senior Researcher, Health Technology Assessment Task Force, Center for Drug Evaluation, Taipei, Taiwan

 

Ming-Chin Yang PhD, Associate Professor, Medical Administration Institute, National Taiwan University, Taipei, Taiwan

 

Hsiao-Yi Lin MD, FACR, Chief, Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taipei Veterans General Hospital, Taiwan, and (adjunct position) Associate Professor, National Yang-Ming University, Taipei, Taiwan

 

India

 

Urmila Mukund Thatte PhD, DNB, MD, MBBS, Jt. Secretary, ISPOR India Chapter, Professor and Head, Department of Clinical Pharmacology, Topiwala National Medical College, BYL Nair Charitable Hospital, Mumbai, India

 

Jawahar S. Bapna PhD, MD, MB, Secretary, ISPOR India Chapter, and Professor, Pharmaceutical Management, Indian Institute of Health Management Research, Jaipur, India

 

Indonesia

 

Ahmad Fuad Afdhal Phd, Chief Executive Officer, Center for Socio-Economic Studies in Pharmacy, Jakarta, Indonesia

 

Japan

 

Isao Kamae MD, DrPH, Co-chair, ISPOR 1st Asia-Pacific Conference, Professor and Chair, Graduate School of Health Management, Keio University, Kanagawa, Japan

 

Shunya Ikeda MD, MS, DMSc, President, ISPOR Japan Chapter, and Professor of Public Health and Pharmacoeconomics, Department of Pharmaceutical Sciences, School of Pharmacy, International University of Health and Welfare, Tochigi, Japan

 

Takashi Fukuda PhD, Associate Professor, Department of Health Economics and Epidemiology Research

Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

 

Hiroyuki Sakamaki MBA, Dr Med Sci., Professor, Department of Clinical Economics, Faculty of Pharmaceutical Science, Meijo University, Nagoya, Japan

Malaysia

 

Syed Mohamed Aljunid MD, MSc, PhD, FAMM, President, ISPOR Malaysia Chapter, Professor of Health Economics, and Consultant Public Health Medicine, Senior Research Fellow, United Nations University-International Institute of Global Health (UNU-IIGH), and Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia

Mongolia

 

Ganbat Byambaa MD, MPH, MHSM (Curtin), PhD, Associate Professor and Dean for Graduate training, Scientific Secretary of Academic Council, Health Sciences University of Mongolia, Ulaanbaatar, Mongolia

 

Pakistan

 

Aamir Hameed MBBS, FCPS (Internal Medicine), FCPS (Cardiology), Assistant Professor and Consultant Cardiologist, Cardiology Section, Department of Medicine, Aga Khan University, Karachi, Pakistan

 

Anwarul Hassan GilaniMSc, PhD; S.I, President, ISPOR Pakistan Chapter, and National Professor of Pharmacology, Director, Drug Discovery and Natural Products Research, and Vice Chair, Research and Graduate Studies, Department of Biological and Biomedical Sciences, Aga Khan University Medical College, Karachi, Pakistan

 

Muhammad Ashraf Janjua BA. MA, Dean, College of Business Management, and Chief Editor, Pakistan Business Review, Creek, Karachi, Pakistan

 

Philippines

 

Madeleine R. Valera MD, MScIH (Heidelberg), Senior Vice President for Health Finance Policy and Services Sector, Philippine Health Insurance Corporation, Pasig City, Philippines


Singapore

 

Shu-Chuen Li PhD, MS, MBA, Professor, Chair & Head, Discipline of Pharmacy & Experimental Pharmacology, School of Biomedical Sciences, University of Newcastle, Callaghan NSW, Australia, and Visiting Professor, Department of Pharmacy, National University of Singapore, Singapore

 

South Korea

 

Bong-Min Yang PhD, Chair, ISPOR 3rd Asia-Pacific Conference, and Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea

 

Eui-Kyung Lee PhD, Professor, Graduate School of Clinical Pharmacy, Sookmyung Women’s University, Seoul, South Korea

 

Sang-Cheol Bae MD, PhD, MPH, Professor and Director, The Hospital for Rheumatic Diseases, and Head, Section for  Clinical Epidemiology and Economics, Hanyang University, Seoul, South Korea

 

Eun-Young Bae PhD, Assistant Professor, Department of Health Policy and Management, Sangji University, Kangwon-do, South Korea

Thailand

 

Nathorn Chaiyakunapruk PharmD, PhD, Director of Center of Pharmaceutical Outcomes Research, and Associate Professor of Pharmacy, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand

Surachat Ngorsuraches, PhD. RPh, Chair, ISPOR 4th Asia-Pacific Conference Associate Dean for Planning and Development, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkla, Thailand

 

Vithaya Kulsomboon PhD, Chair, ISPOR 4th Asia-Pacific Conference, President, ISPOR Thailand Chapter, Associate Professor, Chair of Social Pharmacy Department, and Director of Graduate Program in Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand

 

Industry

 

Zhiqiang Guan MD, MPH, Director, Public Affairs & Policy Department, Pfizer China, Beijing, China

 

Alison Tan-Mulligan PhD, MBBS, Health Outcomes & Epidemiology Manager, GlaxoSmithKline Pharmaceuticals (China) Investment Co. Ltd, Shanghai, China

 

Jittrakul Leartsakulpanitch B.Sc.(Pharmacy), Msc, PhD, Outcomes Research Associate, Medical Department, Pfizer (Thailand) Ltd., Bangkok, Thailand

 

Advisory Committee Chair

Mingliang Zhang PhD, Senior Director, Worldwide Market Access, Global Strategic Marketing and Market Access, Johnson and Johnson Pharmaceutical Services, Horsham, PA, USA
E-mail: mzhang5@its.jnn.com

Asia Consortium Advisory Committee Directory

2009-2011 Chair

Mingliang Zhang PhD, Senior Director, Worldwide Market Access, Global Strategic Marketing and Market Access, Johnson and Johnson Pharmaceutical Services, Horsham, PA, USA
E-mail: mzhang5@its.jnn.com

2009-2011 Chair-elect and 2011-2013 Chair

 

Jennifer Sung PharmD, MS, Executive Director, Global Health Economics & Outcomes Research, Novartis, Shanghai, China

Members

 

Asia: Academia & Government

Jeonghoon Ahn PhD, MA, Director, Economic Evaluations, National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, Korea

 

Hye-Young Kang PhD, Associate professor, Graduate School of Public Health,  Executive committee, Institute of Health Services Research, Yonsei University, Seoul, Korea

 

Asia: Consulting and Research Organization

 

Carol Cheng, Chief Operating Officer, International Research-Based Pharmaceutical Manufactures Association (IRPMA), Taipei, Taiwan

 

Bruce Crawford MA, MPH, General Manager, Asia, Adelphi Values, Japan

 

Asia: Industry

 

William Bishop, Director, Government Affairs, Nippon Becton Dickinson Company, Ltd., Tokyo, Japan

 

Kevin C. Chen, Vice President, Asia, International Research-based Pharmaceutical Manufacturing Association, Taipei, Taiwan

 

Seong-Choon Choe MD, PhD, Medical Director, Medical Affairs, Wyeth Korea, Seoul, South Korea

 

Izhar M. Hussain M. Pharm. MBA, Director, Business Excellence & Development, Abbott Laboratories (Pakistan) Ltd.

Sindh, Pakistan

 

Hong Li PhD, MPH, 2005-2007 Chair, Asia Consortium Advisory Committee, Group Director, Outcomes Research, and Vice President, Market Access, China, Bristol-Myers Squibb Company Asia-Pacific, Singapore, Singapore

Jennifer Sung PharmD, MS, Executive Director, Global Health Economics & Outcomes Research, Novartis, Shanghai, China

 

Lillian Yu-Jen Wang MS, Market Access Manager, Novartis (Taiwan) Co., Ltd., Taipei, Taiwan

 

Non-Asia: Academia

 

Rajesh Balkrishnan PhD, Merrell Dow Professor, Ohio State University College of Pharmacy and School of Public Health, Columbus, OH, USA

 

John Bian PhD, Assistant Professor, Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL,  USA

Hua Chen PhD, Department of Clinical and Administration, College of Pharmacy, University of Houston, Texas Medical Center, Houston, TX, USA

 

Jalpa Doshi PhD, Research Assistant Professor of Medicine, General Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA

 

Christian Gericke, MD MPH MSc FACP, Professor and Chair in Public Health Policy, The University of Adelaide, Adelaide SA, Australia

Jeff J. Guo B. Pharm., PhD, 2007-2009 Chair, Asia Consortium Advisory Committee, and Associate Professor of Pharmacoeconomics & Pharmacoepidemiology, Division of Pharmacy Practice & Administrative Sciences, James L. Winkle College of Pharmacy (& Faculty Research Fellow, Institute for the Study of Health), University of Cincinnati Medical Center, 3225 Eden Ave, Cincinnati, OH, USA

 

Dong-Churl Suh MBA, Ph.D, Associate Professor, Department of Pharmacy Practice and Administration, College of Pharmacy--Busch Campus Rutgers, the State University of New Jersey, Piscataway, NJ, USA

 

Peter K. Wong, PhD, MBA, MS, RPh, Vice President, Quality and Clinical Effectiveness, Mercy Health Partners, Southwest Ohio, Cincinnati, Ohio, USA

Hong Xiao PhD, Associate Professor, Division of Economic, Social and Administrative Pharmacy, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA

Non-Asia: Consulting

 

Brian P. Harrigan BA, Chief Operating Officer, Oxford Outcomes, Vancouver, B.C., V6B 1P1, Canada

 

Non-Asia: Industry

 

Jim P. Doherty MSHA, PhD, GlaxoSmithKline, Global Health Outcomes-Manager, Anti-infectives/Antivirals/Disease of Developing World, Research Triangle Park, NC, USA

Sandeep Duttagupta PhD, Senior Director, Market Access Leader, Emerging Markets Business Unit. Pfizer Inc., New York, NY, USA

 

Amy Guo PhD, Director, Health Economics Research & Outcomes, Berlex Lavoratories, Wayne, NJ, USA

 

Xing-Yue Huang MS,PhD, Health Economics Sr. Manager, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA, USA

 

Sheldon Kong PhD, Head, Global Outcomes Research, Merck & Company, Inc., Whitehouse Station, NJ, USA

 

Linda C. Koo PhD, Director, Discovery Medicine and Epidemiology, AstraZeneca LP, Wilmington, DE, USA

 

Roger G. Luo PhD, MA, MS, Associate Director, Health Economics & Outcomes Research, AstraZeneca, Wilmington, DE, USA

 

Siew Hwa Ong MSc, Health Economics Manager, ID, Novartis Pharma AG, Health Economics & Outcomes Research
Infectious Diseases, Transplantation & Immunology Business Unit (IDTI BU), Novartis Pharma AG, Basel, Switzerland

 

Manny Papadimitropoulos PhD, Director, Health Outcomes Research, Intercontinental Region and Japan, Eli Lilly and Company, Toronto, Ontario, Canada

 

Eugene G Salole PhD, Associate Director, Health Technology Assessment, Asia Region, Pfizer Worldwide Phamaceutical Operations, Australia, West Ryde, NSW, Australia

 

Fang Wang MD, PhD, Medical Director, Clinical Research, Cephalon, Inc., Frazer, PA, USA

 

Jasmanda Hsiao-Hui Wu PhD, MPH, Associate Director, Outcomes Research, Ortho-McNeil Janssen Scientific Affairs, L.L.C., Johnson & Johnson, Titusville, NJ, USA

 

Mingliang Zhang PhD, Senior Director, Worldwide Market Access, Global Strategic Marketing and Market Access, Johnson and Johnson Pharmaceutical Services, Horsham, PA, USA

 

Zhongyun Zhao PhD, Director, Global Health Economics, Amgen Inc., Thousand Oaks, CA, USA

ISPOR Asia-Pacific Medical Device & Diagnostics Council Directory

ISPOR Asia-Pacific Medical Device & Diagnostics Council

 

2008-2010 Chair & Vice Chair

 

Jie Chen PhD, Director, Key Lab of Health Technology Assessment, Consultant, National Institute of Hospital Administration, Ministry of Health, and Professor, School of Public Health, Fudan University, Shanghai, China

 

Madeleine R. Valera MD, MScIH (Heidelberg), Senior Vice President for Health Finance Policy and Services Sector, Philippine Health Insurance Corporation, Pasig City, Philippines

 

2008-2010 Chair-elect & Vice Chair-elect and 2010-1012 Chair & Vice Chair

 

Isao Kamae MD, DrPH, Professor and Chair, Graduate School of Health Management, Keio University, Kanagawa, Japan

 

Hye-Young Kang PhD, Associate professor, Graduate School of Public Health,  Executive committee, Institute of Health Services Research, Yonsei University, Seoul, South Korea

 

Members

 

China Mainland

 

Government:

Xiaoli Tang MSc, MA, Deputy Chief, Policy Davison, Medical Insurance Department, Ministry of Labor & Social Security,  Beijing, China

 

Anna Xi Zhao MD, MBA, Trade & Investment Manager (LifeSciences), British Embassy, Beijing, China

 

Academia:

Jie Chen PhD, Director, Key Lab of Health Technology Assessment, Consultant, National Institute of Hospital Administration, Ministry of Health, and Professor, School of Public Health, Fudan University, Shanghai, China

 

Yingyao Chen PhD, Associate professor, School of Public Health, Fudan University, Shanghai, China

 

Taiwan

 

Government:

Cheng-Hua Lee MD, PhD, Vice President & C.I.O., Bureau of National Health Insurance, Department of Health, Taipei, Taiwan

 

Tony Yen-Huei Tarn MS, PhD, Senior Researcher, Health Technology Assessment Task Force, Center for Drug Evaluation, Taipei, Taiwan

 

Academia:

Hsien-Li Kao MD, Associate Professor, Director, Cardiac Cath Lab, National Taiwan University School of Medicine & Hospital, Email: hsienli_kao@yahoo.com

Ming-Chin Yang PhD, Associate Professor, Medical Administration Institute, National Taiwan University, Taipei, Taiwan

Japan

 

Government:

Toshio Nagae, President of CMIC MPSS, (Marketing Promotion & Sales Support), And that of PCN, Patient Community Network, Tokyo, Japan

 

Academic:

Isao Kamae MD, DrPH, Professor and Chair, Graduate School of Health Management, Keio University, Tokyo, Japan, Kanagawa, Japan


Malaysia

 

Hospital:

Kui-Hian Sim MBBS, Head, Department of Cardiology, Head, Clinical Research Centre (CRC), Sarawak General Hospital, Adjunct Professor, Faculty of Medicine & Health Sciences, University Malaysia Sarawak (UNIMAS), Sarawak, Malaysia

 

Teck Onn Lim PhD, Head, Clinical Research Centre, Kuala Lumpur Hospital, Ministry of Health, Kuala Lumpur, Malaysia

 

Philippines

 

Government:

Madeleine R. Valera MD, MScIH (Heidelberg), Senior Vice President for Health Finance Policy and Services Sector, Philippine Health Insurance Corporation, CityState Center, Pasig City, Philippines

Agnette P. Peralta, Director, Bureau of Health Devices and Technology, Department of Health, Philippines, Manila, Philippines

 

Singapore

 

Academia:

Kai Hong Phua AB SM PhD, 2006-2008 Vice Chair, 2007-2008 Chair, and Joint Professor, Health Policy and Management, Lee Kuan Yew School of Public Policy, National University of Singapore, Singapore, Singapore

 

Meng Kin Lim, Community Occupational & Family Medicine, National University of Singapore, Singapore, Singapore

 

Hospital:

Yean Teng Lim, Consultant Cardiologist, Cardiology Associates, Singapore, Singapore

 

South Korea

 

Academic:

Hye-Young Kang PhD, Associate professor, Graduate School of Public Health,  Executive committee, Institute of Health Services Research, Yonsei University, Seoul, South Korea

 

Industry

Edwards Lifesciences Japan:

Huimin Wang, Corporate Vice Presidnet, Edwards Lifesciences, Tokyo, Japan

 

Johnson & Johnson Asia Pacific:

Ashoke Bhattacharjya PhD, Executive Director, Health Economics and Policy, Johnson & Johnson Medical Asia Pacific, New Delhi, India

 

Medtronic Korea:

Sang Soo Lee MBA, Therapy Value Partner Manager, Reimbursement, PR and Web-Communication, Medtronic Korea Co., Ltd., Seoul, South Korea

 

Stryker Pacific Australia:

George Faithfull, Vice President, Regulatory Affairs and Quality Assurance, Stryker Pacific, NSW, Australia

 

Siemens China Ltd Medical Solutions Group:

Han Dehui (Davey), MS, MD, General Manager, Regulatory Affairs and Quality Management, Siemens China Ltd Medical Solutions Group, Beijing, China

 

Pfizer Inc. China:

Zhiqiang Guan MD, MPH, 2006-2007 Chair, and Director, Public Affairs & Policy Department, Pfizer China, Beijing, China

 

ISPOR Asia-Pacific Medical Device & Diagnostics Council Advisory Committee

 

2008-2010 Chair

 

Miguel Valentin, Director, Health Economics – International, Boston Scientific Corporation, Natick, MA, USA

 

Members

 

Paul Barry, Boston Scientific, Washington, DC, USA

 

Jeff Farkas, Sr. Director, Health Policy & Payment, Medtronic, Inc., Washington, DC, USA

 

Stephen Hull, Vice President, Global Strategy & Analysis Dept, Advanced Medical Technology Association (AdvaMed), Washington, DC, USA

 

Teng Chuan Khoo PhD, Vice President, Strategic Medical Affairs, Johnson & Johnson Medical Asia-Pacific, Singapore, Singapore

 

Craig Kramer, Vice President, Government Affairs, Johnson & Johnson, New Brunswick, NJ, USA

 

Chris Miller, Sr. Director, Healthcare Economics - Asia Pacific, Medtronic, Inc, Tokyo, Japan

 

Nancy Travis MIA, 2006-2008 Chair, and Vice President, Global Strategy and Analysis (Asia), Advanced Medical Technology Association (AdvaMed), Washington, DC, USA

To the Top


Back to Asia Consortium main page